sb 203580 has been researched along with beta-elemene in 1 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (beta-elemene) | Trials (beta-elemene) | Recent Studies (post-2010) (beta-elemene) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 258 | 1 | 211 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ding, X; Huang, CX; Jia, YC; Wang, YZ; Xu, YH; Yao, YQ | 1 |
1 other study(ies) available for sb 203580 and beta-elemene
Article | Year |
---|---|
Anti-tumor effect of beta-elemene in glioblastoma cells depends on p38 MAPK activation.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Enzyme Inhibitors; Glioblastoma; Humans; Imidazoles; Mice; Mice, Nude; p38 Mitogen-Activated Protein Kinases; Pyridines; Rats; Sesquiterpenes; Signal Transduction; Xenograft Model Antitumor Assays | 2008 |